Devyser Diagnostics Ab · OMXSTO:DVYSR

Devyser Diagnostics Ab — Q1 2025 Earnings Presentation

24 slides from Devyser Diagnostics Ab's earnings presentation, Apr 29, 2025

1. Slide 1: Earnings call Q1 2025

   Devyser Earnings call Q1 2025 April 29, 2025

2. Slide 2: Today’s presenters

   Today’s presenters Fredrik Dahl Sabina Berlin Theis Kipling Interim CEO CFO CCO

3. Slide 3: First quarter financials

   First quarter financials  Revenue • Sales 55 MSEK (51 MSEK) • Growth 8%  Gross margin 83%  EBIT -21 MSEK, including -8 MSEK in one-offs and -6 MSEK in F/X impact  Cash position 114 MSEK 3

4. Slide 4: Strategy: Clinical genetics labs and Transplantation labs

   Strategy Clinical genetics labs Transplantation labs summary 7 F Products * Hereditary cancer + Post-transplantation * Reproductive health * Cystic fibrosis * Cardiovascular diseases + Hematology Sales channels Direct sales and distributors Partnership and direct sales Strategy Premier partner for a

5. Slide 5: Post-transplantation - decentralized vs. centralized

   Post-transplantation - decentralized vs. centralized Decentralized Patient Devyser customers o| 2 fo f Local transplant laboratories Closer proximity to patients Faster turnaround time Increased reliability and higher performance ——}> Dvysr. Centralized Patient Local clinic ; CareDx © 4 @ natera Hig

6. Slide 6: Accept cfDNA FDA Clinical Strategy

   Accept cfDNA FDA Clinical Strategy Sample Collection - Enrollment Study Clinical Reproducibility Clinical Accuracy - • 3-5 transplant centers - Testing Study Testing Study • ~300 patients enrolled • 3 Testing Sites • 1 Testing Site (External) (1 Internal & 2 External) FDA Submission Draft IUO Softwa

7. Slide 7: R&D update and product launches

   R&D update and product launches · Transplantation labs in US ready to evaluate our cf DNA technique. o Confirming our strategy of bringing home diagnostics to the lab instead of using service labs. · HLA loss on schedule to be launched before summer. o Addressing important clinical need in patients

8. Slide 8: More highlights

   More highlights · Securing IVDR approval for Devyser RHD, our first Class D IVD product and a major milestones for us this year. o The highest risk classification under EU regulation o Capability to support the development of any IVD product, regardless of risk class. · Several value generating acti

9. Slide 9: First quarter 2025

   First quarter 2025

10. Slide 10: First quarter

    First quarter  Revenue • Sales 54.8 MSEK (50.7 MSEK) • Growth +7.9% 10

11. Slide 11: Quarterly net sales

    Quarterly net sales SEK million PS, i y 70 60 50 40 30 20 10 i) se Dvysr.

12. Slide 12: Sales by region

    Sales by region EMEA 47.0 Asia-Pacific 17 North and South . 6.0 America Total 54.8 Dvysr. 50.7 100.0% 36.0% 7.9%

13. Slide 13: Sales by sales channel

    Dvysr. Sales by sales channel Direct sales 40.5 38.3 75.5% 73.9% 5.8% Distributor sales 14.2 12.4 24.5% 25.9% 14.6% Total 54.8 50.7 100.0% 100.0% 7.9%

14. Slide 14: First quarter

    First quarter  Revenue • Sales 54.8 MSEK (50.7 MSEK) • Growth +7.9%  Gross margin 83.4% (82.7%) 14

15. Slide 15: First quarter

    First quarter  Revenue • Sales 54.8 MSEK (50.7 MSEK) • Growth +7.9%  Gross margin 83.4% (82.7%)  EBIT • -20.5 MSEK (-12.2) • -8 MSEK one-offs • -6 MSEK F/X 15

16. Slide 16: First quarter

    First quarter  Revenue • Sales 54.8 MSEK (50.7 MSEK) • Growth +7.9%  Gross margin 83.4% (82.7%)  EBIT • -20.5 MSEK (-12.2)  Strong financial position • 114 MSEK in liquidity • No debts 16

17. Slide 17: Highlights Q1 and Commercial outlook

    Highlights Q1 and Commercial outlook

18. Slide 18: Update on Thermo Fisher Scientific

    Update on Thermo Fisher Scientific  A decent Q1 2025 despite the Q4 2024 stock up orders  Continued strong momentum across Europe and US whereas rest of the world is slowly ramping up  General revenue build up is expected to increase quarter by quarter throughout the year  FDA program well under

19. Slide 19: North America update

     Devyser Genomic Laboratories in Atlanta is on track with:  Accept cfDNA is following timeline for reimbursement during summer 2025 – partnering discussions are ongoing  Cyted collaboration following plan – revenues and volumes to North consistently increase throughout the year  RHD testing rema

20. Slide 20: Europe

    • Italy, Benelux and Nordics where impacted by some large customers placing orders in Q4 2024 which made Q1 a soft quarter in total for direct sales • Strong Q1 performance however in several direct Europe markets i.e. Spain, France, UK and DACH with ~50% growth vs Q1 2024 • Across Europe we increas

21. Slide 21: Other

    • We had a strong Q1 on many fronts incl. All time high number of new leads – mainly driven by the US • Busy year ahead of us with several new product launches incl. Kits, software and regulatory approvals Other • Our four most recent product launches accumulated ~18% of total revenues the past year

22. Slide 22: Going forward

    Going forward • Executing on updated strategy • Continue to work on organizational efficiency • New product launches • Continue our way to profitability 22

23. Slide 23: Q&A

    O&A Dvysr.

24. Slide 24: Thank you!

    Thank you! Connect with us www.devyser.com

Devyser Diagnostics — Q1 2025 Earnings Presentation on 6ix